trending Market Intelligence /marketintelligence/en/news-insights/trending/nLoxpKzMWtEAE0L3_WCzVA2 content esgSubNav
In This List

SkinBioTherapeutics starts trading on AIM

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


SkinBioTherapeutics starts trading on AIM

SkinBioTherapeutics plc's ordinary shares started trading on the London Stock Exchange's AIM market on April 5 under the ticker SBTX.

The company's IPO raised £4.5 million in gross proceeds with the issuance of 118,708,494 ordinary shares at 9 pence per share, including a cornerstone investment from U.K. equity investor Seneca Partners Ltd.

Estimated net proceeds from the offering were £4.1 million.

Cairn Financial Advisers LLP was the nominated adviser for the IPO and Turner Pope Investments Ltd. acted as the broker.

OptiBiotix Health PLC holds a significant stake in SkinBioTherapeutics.